News - Enbrel, Anti-Arthritics/Rheumatics

Filter

Popular Filters

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19-09-2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

German pharma watch dog finds benefits for biologicals in RA

30-08-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined nine biotechnologically…

Anti-Arthritics/RheumaticsBiotechnologyCimziaEnbrelEuropeHumiraKineretMabTheraOrenciaPharmaceuticalPricingRegulationRemicadeRoActemraSimponi Injection

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Generics triple-therapy just as effective as brand-name Enbrel, new study shows

13-06-2013

Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…

AmgenAnti-Arthritics/RheumaticsEnbrelGenericsmethotrexatePharmaceuticalResearch

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

17-04-2013

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?

13-02-2013

Since 2004, the market for monoclonal antibodies (MAbs) in rheumatoid arthritis (RA) has experienced…

Anti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingPharmaceuticalRemicade

Global rheumatology market controlled by Enbrel, Humira and Remicade

24-12-2012

The global rheumatology therapeutics market has been forecast to increase at a compound annual growth…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyCelebrexEnbrelGlaxoSmithKlineGlobalHumiraMarkets & MarketingPfizerPharmaceuticalRemicadeTakeda PharmaceuticalsUloric

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA

07-10-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Enbrel gets highest rating among RA biologicals by surveyed US patients

02-09-2012

For surveyed rheumatoid arthritis (RA) patients on biologic therapy, the benefits outweigh the risks…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEnbrelMarkets & MarketingmethotrexateNorth AmericaPfizerPharmaceutical

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

US rheumatologists continue to increase use of biologics for RA treatment

29-03-2012

Biologic agents remain the preferred treatment for patients suffering from rheumatoid arthritis (RA),…

ActemraAnti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingNorth AmericaOrenciaPharmaceuticalRituxantofacitinib

Amgen’s gets new US patent for Enbrel, giving protection until 2028

24-11-2011

Global biotech leader Amgen (Nasdaq: AMN) has announced the issuance of a new patent, US Patent No 8,063,182,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEnbrelNorth AmericaPatentsPharmaceuticalRoche

Study identifies factors linked with better medication response for treatment of juvenile arthritis

07-11-2011

Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept…

AmgenAnti-Arthritics/RheumaticsEnbreletanerceptPfizerPharmaceuticalResearch

Remicade, Humira and Enbrel made up 40% of the immunomodulators market in 2010; report

23-08-2011

Tumor necrosis factor (TNF) inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis…

Anti-Arthritics/RheumaticsBenlystaEnbrelGilenyaHumiraMarkets & MarketingNeurologicalPharmaceuticalRemicade

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top